Kewaunee Scientific Reports Record $282M Revenue for Fiscal 2026
Kewaunee Scientific (NASDAQ:KEQU) reported record revenue of $282 million for the fiscal year ended April 30, 2026. This marks a nearly 14% compound annual growth rate since fiscal 2021 and reflects strong performance across its segments. The Lab Products Group saw sales rise by 19.8%, driven largely by NuAire's full-year contribution following the acquisition in November 2024, while international segment revenue increased by 9.9%. EBITDA totaled $22.4 million for fiscal 2026 as operational improvements and earnings leverage took effect. Kewaunee also reduced long-term debt by approximately $20 million and fully repaid the NuAire seller note, improving its debt-to-equity ratio to 1.0x from 0.99x. The company outlined plans for continued investment in product development, manufacturing capacity, international expansion, and potential acquisitions as it aims toward fiscal 2027 growth.
Tickers: $KEQU
Topics: debt reduction growth strategy revenue segment performance